Endobronchial lung volume reduction is currently recommended as a therapeutic option for severe chronic obstructive pulmonary disease with hyperinflation. Since December 2018, two-valve systems have been authorized by the Food and Drug Administration (FDA), sparking considerable interest in this novel therapy for chronic obstructive pulmonary disease (COPD).
Although the technical installation of endobronchial valves is rather simple, this study focuses on the interdisciplinary approach to diagnosis, assessment, and follow-up, as well as procedural approaches for endoscopic lung volume reduction implementation.
